186 related articles for article (PubMed ID: 19494617)
1. New acquisitions in therapy of secondary hyperparathyroidism in chronic kidney disease and peritoneal dialysis patients: role of vitamin D receptor activators.
Brancaccio D; Cozzolino M; Pasho S; Fallabrino G; Olivi L; Gallieni M
Contrib Nephrol; 2009; 163():219-226. PubMed ID: 19494617
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism.
Cozzolino M; Brancaccio D
Expert Opin Pharmacother; 2008 Apr; 9(6):947-54. PubMed ID: 18377338
[TBL] [Abstract][Full Text] [Related]
4. Oral paricalcitol versus oral calcitriol in continuous ambulatory peritoneal dialysis patients with secondary hyperparathyroidism.
Jamaluddin EJ; Gafor AH; Yean LC; Cader R; Mohd R; Kong NC; Shah SA
Clin Exp Nephrol; 2014 Jun; 18(3):507-14. PubMed ID: 23903802
[TBL] [Abstract][Full Text] [Related]
5. Vitamin D analogues for the management of secondary hyperparathyroidism.
Martin KJ; González EA
Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S34-40. PubMed ID: 11689385
[TBL] [Abstract][Full Text] [Related]
6. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism.
Wesseling-Perry K; Pereira RC; Sahney S; Gales B; Wang HJ; Elashoff R; Jüppner H; Salusky IB
Kidney Int; 2011 Jan; 79(1):112-9. PubMed ID: 20861820
[TBL] [Abstract][Full Text] [Related]
7. Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism: understanding the differences among therapies.
Brancaccio D; Bommer J; Coyne D
Drugs; 2007; 67(14):1981-98. PubMed ID: 17883283
[TBL] [Abstract][Full Text] [Related]
8. Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism.
Borrego Utiel FJ; Bravo Soto JA; Merino Pérez MJ; González Carmelo I; López Jiménez V; García Álvarez T; Acosta Martínez Y; Mazuecos Blanca MA
Nefrologia; 2015; 35(4):363-73. PubMed ID: 26306956
[TBL] [Abstract][Full Text] [Related]
9. Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients.
Capuano A; Serio V; Pota A; Memoli B; Andreucci VE
J Nephrol; 2009; 22(1):59-68. PubMed ID: 19229819
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy and safety of paricalcitol versus vitamin D receptor activators for dialysis patients with secondary hyperparathyroidism: a meta-analysis of randomized controlled trials.
Xie Y; Su P; Sun Y; Zhang H; Zhao R; Li L; Meng L
BMC Nephrol; 2017 Aug; 18(1):272. PubMed ID: 28841848
[TBL] [Abstract][Full Text] [Related]
11. Management of secondary hyperparathyroidism in uremic patients: the role of the new vitamin D analogs.
Brancaccio D; Cozzolino M; Galassi A; Chiarelli G; Butti A; Bellasi A; Rocca-Rey L; Volpi A; Anelli A; Zoni U; Fusaro M; Brambilla C; Missaglia E; Crovetto C; Russo M; Longhini C; Provenzano R; Incalcaterra F; Cerasola G; Li Vecchi M; Gallieni M
J Nephrol; 2007; 20(1):3-9. PubMed ID: 17347966
[TBL] [Abstract][Full Text] [Related]
12. [Paricalcitol - a selective vitamin D receptor activator for secondary hyperparathyroidism in patients with chronic kidney disease].
Matuszkiewicz-Rowińska J; Żebrowski P
Wiad Lek; 2016; 69(5):756-759. PubMed ID: 28033603
[TBL] [Abstract][Full Text] [Related]
13. Vitamin D, vitamin D receptor and the importance of its activation in patients with chronic kidney disease.
Bover J; Egido J; Fernández-Giráldez E; Praga M; Solozábal-Campos C; Torregrosa JV; Martínez-Castelao A
Nefrologia; 2015; 35(1):28-41. PubMed ID: 25611831
[TBL] [Abstract][Full Text] [Related]
14. Nonclassical aspects of differential vitamin D receptor activation: implications for survival in patients with chronic kidney disease.
Andress D
Drugs; 2007; 67(14):1999-2012. PubMed ID: 17883284
[TBL] [Abstract][Full Text] [Related]
15. New therapies: calcimimetics, phosphate binders and vitamin D receptor activators.
Cannata-Andía JB; Rodriguez-García M; Román-García P; Tuñón-le Poultel D; López-Hernández F; Rodríguez-Puyol D
Pediatr Nephrol; 2010 Apr; 25(4):609-16. PubMed ID: 20151157
[TBL] [Abstract][Full Text] [Related]
16. Paricalcitol capsules for the control of secondary hyperparathyroidism in chronic kidney disease.
Cheng S; Coyne D
Expert Opin Pharmacother; 2006 Apr; 7(5):617-21. PubMed ID: 16553577
[TBL] [Abstract][Full Text] [Related]
17. Paricalcitol for secondary hyperparathyroidism in renal transplantation.
Trillini M; Cortinovis M; Ruggenenti P; Reyes Loaeza J; Courville K; Ferrer-Siles C; Prandini S; Gaspari F; Cannata A; Villa A; Perna A; Gotti E; Caruso MR; Martinetti D; Remuzzi G; Perico N
J Am Soc Nephrol; 2015 May; 26(5):1205-14. PubMed ID: 25194004
[TBL] [Abstract][Full Text] [Related]
18. Successful Conversion From Parenteral Paricalcitol to Pulse Oral Calcitriol for the Management of Secondary Hyperparathyroidism in Hemodialysis Patients.
Kumar J; Tran NT; Schomberg J; Streja E; Kalantar-Zadeh K; Pahl M
J Ren Nutr; 2016 Jul; 26(4):265-9. PubMed ID: 27038806
[TBL] [Abstract][Full Text] [Related]
19. Mortality risk among hemodialysis patients receiving different vitamin D analogs.
Tentori F; Hunt WC; Stidley CA; Rohrscheib MR; Bedrick EJ; Meyer KB; Johnson HK; Zager PG;
Kidney Int; 2006 Nov; 70(10):1858-65. PubMed ID: 17021609
[TBL] [Abstract][Full Text] [Related]
20. Comparison between paricalcitol and active non-selective vitamin D receptor activator for secondary hyperparathyroidism in chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials.
Cai P; Tang X; Qin W; Ji L; Li Z
Int Urol Nephrol; 2016 Apr; 48(4):571-84. PubMed ID: 26748501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]